GEN Exclusives

More »

GEN News Highlights

More »
May 2, 2007

Artemis and Taconic Acquire Kinase-Related Discovery IP from CGI

  •  Taconic Farms and Artemis Pharmaceuticals have jointly acquired the worldwide rights to the ASKA technology from CGI Pharmaceuticals. This approach to in vivo kinase-related drug discovery is based on the replacement of a normal kinase with a selectively modified kinase or ASKA (Analogue Sensitive Kinase Allele) in genetically modified mice.

    Under the terms of the transaction, Artemis and Taconic are assigned the entire portfolio of ASKA IP rights as well as know-how, trade secrets, and materials developed by CGI. Included are the rights to patents based on the chemistry and molecular biology work of Dr. Kevan Shokat, Ph.D., inventor of the ASKA technology.

    Artemis and Taconic will generate, market, and distribute ASKA transgenic mouse models in which a fully functional ASKA replaces the normal kinase gene.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?